Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Akiyoshi Kasuga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2234-1135; OpenAlex author ID A5066075096. Sources: OpenAlex.

Their work

Papers
31 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 8 papers · 2022: 6 papers · 2023: 8 papers · 2024: 2 papers · 2025: 1 paper

Papers 31

  1. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. Co-author DOI 10.2169/internalmedicine.3577-24↗
  2. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. Co-author DOI 10.1002/deo2.360↗
  3. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyae028↗
  4. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  5. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  6. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  7. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  8. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  9. Outcomes of lung oligometastasis in pancreatic cancer. Co-author DOI 10.1093/jjco/hyad111↗
  10. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Co-author DOI 10.2169/internalmedicine.0730-22↗
  11. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  12. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  13. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1093/jjco/hyac145↗
  14. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  15. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  16. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  17. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  18. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Co-author DOI 10.1007/s10147-020-01827-2↗
  19. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-021-01912-0↗
  20. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  21. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Co-author DOI 10.1016/j.pan.2021.03.006↗
  22. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa247↗
  23. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyab014↗
  24. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗
  25. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… Co-author DOI 10.1097/mpa.0000000000001801↗
  26. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  27. Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. Co-author DOI 10.1055/a-1244-1989↗
  28. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. First author DOI 10.1186/s12885-020-06945-8↗
  29. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. Co-author DOI 10.1007/s10637-018-0589-6↗
  30. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemo… Co-author DOI 10.1007/s00280-017-3263-3↗
  31. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refrac… Co-author DOI 10.1007/s00280-014-2665-8↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takashi Sasaki · 27 shared papers, 2020–2025 · strength 3.97
  2. Tsuyoshi Takeda · 27 shared papers, 2020–2025 · strength 3.97
  3. Masato Ozaka · 27 shared papers, 2020–2025 · strength 3.97
  4. Naoki Sasahira · 27 shared papers, 2020–2025 · strength 3.97
  5. Takafumi Mie · 26 shared papers, 2020–2025 · strength 3.79
  6. Takaaki Furukawa · 25 shared papers, 2020–2025 · strength 3.58
  7. Masato Matsuyama · 23 shared papers, 2020–2023 · strength 3.18
  8. Takeshi Okamoto · 18 shared papers, 2021–2025 · strength 2.87
  9. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  10. Hiroki Nakagawa · 7 shared papers, 2022–2025 · strength 1.25
  11. Yu Takahashi · 6 shared papers, 2020–2023 · strength 0.81
  12. Yosuke Inoue · 3 shared papers, 2020–2023 · strength 0.41
  13. Akio Saiura · 2 shared papers, 2020–2023 · strength 0.28
  14. Manabu Takamatsu · 2 shared papers, 2021–2022 · strength 0.25
  15. Takahisa Matsuda · 1 shared paper, 2024 · strength 0.21
  16. Tsuyoshi Hamada · 1 shared paper, 2023 · strength 0.16
  17. Atsushi Oba · 1 shared paper, 2023 · strength 0.15
  18. Yosuke Inoue · 1 shared paper, 2023 · strength 0.15
  19. Hiromasa Takaishi · 2 shared papers, 2017–2018 · strength 0.14
  20. Takanori Kanai∥ · 2 shared papers, 2017–2018 · strength 0.14
  21. Yasuo Hamamoto · 2 shared papers, 2017–2018 · strength 0.14
  22. Akio Saiura · 1 shared paper, 2022 · strength 0.13
  23. Yuta Ushida · 1 shared paper, 2022 · strength 0.13
  24. Naohiro Okano · 2 shared papers, 2015–2018 · strength 0.13
  25. Yoshihiro Ono · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.